uricosurics, and other interventions have failed to achieve the SU target, and who continue to have frequent gout flares (â‰¥2 flares/year) OR who have nonresolving subcutaneous tophi. Switching to pegloticase over continuing current ULT is strongly recommended against for patients with gout for whom XOI treatment, uricosurics, and other interventions have failed to achieve the SU target, but who have infrequent gout flares (<2 flares/year) AND no tophi. In clinical trials, patients with 3 or